Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134598 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23199749 | 0.85 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1134480 | 0.85 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6350404 | 0.83 | NPC1 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1134541 | 0.82 | CHRNA7 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1134470 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL652089 | 0.81 | GPR119 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL652088 | 0.81 | GPR119 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL6359483 | 0.79 | PRMT5 (0.52) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL7685793 | 0.78 | CHRNB4 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | claimed |
| EP-3802541-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-04-14 | — | — | EP | claimed |
| CN-112243440-A | Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-01-19 | — | — | CN | claimed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802541-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-04-14 | — | — | EP | disclosed |
| CN-112243440-A | Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | CHRNB2 1327/4885CHRNA4 1249/4885CHRNB4 1283/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | CHRNB2 1327/4885CHRNA4 1249/4885CHRNB4 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.